We are developing the next generation of personalized immunotherapies to help revolutionize the treatment of people with cancer and other debilitating diseases.
BioNTech develops tailored treatments for cancer and other diseases with high unmet medical need through its world-class science and disruptive research platforms:
BioNTech’s commercial strategy is to collaborate with selected partners that have a similar drive and commitment in developing and commercializing truly innovative and disruptive immunotherapies.
BioNTech develops and commercializes a broad product pipeline using different scientific approaches and cutting-edge technology platforms. BioNTech´s clinical pipeline represents a number of industry firsts.
